SG Americas Securities
TERN

SG Americas Securities’s Terns Pharmaceuticals TERN Stock Holding History

SG Americas Securities’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.2M Sell
22,774
-21,083
-48% -$866K ﹤0.01% 1643
2025
Q4 		$1.77M Buy
+43,857
New +$1.01M ﹤0.01% 1604
2025
Q2 		– Sell
-413,822
Closed -$1.14M – 3579
2025
Q1 		$1.14M Buy
413,822
+380,489
+1,141% +$1.55M ﹤0.01% 1078
2024
Q4 		$185K Buy
33,333
+9,523
+40% +$64.5K ﹤0.01% 2230
2024
Q3 		$199K Buy
+23,810
New +$196K ﹤0.01% 2500

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

SG Americas Securities's TERN Position: Q1 2026 in Review

SG Americas Securities reduced its Terns Pharmaceuticals (TERN) stake by 48% in Q1 2026, selling an estimated $866K and leaving 22,774 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1643.

SG Americas Securities first reported a position in TERN in Q3 2024 and has held it in 5 quarters since. The position peaked at $1.77M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • SG Americas Securities held 22,774 shares of Terns Pharmaceuticals worth $1.2M as of Q1 2026.
  • SG Americas Securities sold 21,083 Terns Pharmaceuticals shares in Q1 2026, an estimated $866K.
  • Terns Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #1643 holding.
  • SG Americas Securities first reported a position in Terns Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • SG Americas Securities's Terns Pharmaceuticals position peaked at $1.77M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.